11.05.24 -- Your CDMO's Maintenance, From Roof To Floor And Ever More

Verve Therapeutics' Praveen Prasanna, Ph.D., GenSight Biologics' Scott Jeffers, and University of Minnesota's Vaibhav Patel explore the critical considerations and best practices for selecting and managing CDMOs in the development of novel therapies, including advanced therapy medicinal products like cell and gene therapies.

Chief Editor Louis Garguilo starts off our Outsourced Pharma Live with the key questions to ask about the strategic direction of your drug development and manufacturing outsourcing.

Explore how two-column AAV processes can enhance yield and potency while maintaining high-quality standards in the production of gene therapy products.

Experts discuss automated processes, “platformization,” moving early-stage companies into a commercialization structure, and how to support the academics developing these processes.

In this presentation, we examine some of the major challenges that medical writing submission specialists face today and present strategies that can consistently set the stage for success.

Discover how to optimize your CAR T-cell therapy clinical trials with expert insights on genomics, flow cytometry, biomarkers, and clinical operations.

Single-use technology is vital for ensuring the quality and expedited market entry of genomic medicines. Learn how LNP technology is paving the way for a new era of personalized, precise medicine.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

Uncover the secrets behind successes in commercializing and producing commercial cell and gene therapies, including establishing standards of every day, manufacturing operational excellence.

Venkata Indurthi, Ph.D., shares his knowledge and experience with manufacturing RNA, including key upstream and downstream considerations for process development.

Examine how a partner with extensive capabilities and expertise adds value to drug development and helps to solve complex formulation, analytical, and manufacturing challenges our clients face.

Achieve higher titers and robust yield with an optimized, end-to-end lentivirus platform, designed to maximize production and quality for the success of your cell or gene therapy.

Review the common pitfalls encountered in CGT CDMO collaborations, including communication breakdowns, differing regulatory interpretations, and program prioritization challenges.

Witness how IntegriCell delivers high-quality, manufacture-ready cryopreserved leukopaks, vital for consistent and reliable cell therapy production.

In cell and gene therapies, your process is the product. Our team of experts develops, defines, and refines processes for maximum efficiency and scale.

Gain insights into the current challenges in the cell therapy space and discover how Cellistic addresses these issues with iPSC technology, emphasizing regulatory strategies and advanced capabilities.

Our lot release package for the Adeno-Associated Virus (AAV) Vector covers various assays to determine vector-specific characteristics, the presence of adventitious agents, and residuals.

Work with us from start to finish of your product or partner with us at any stage of your project — preclinical through commercial scale.

One Team, One Roof, One CDMO

ReciBioPharm’s expanded biologics services and technologies encompass the entire RNA development and manufacturing value chain, helping to deliver your innovation to patients seamlessly.